OOIR: Observatory of International Research

Papers

(The H4-Index of European Respiratory Journal is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
The right ventricle tamed	1557
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	1010
Chymase-1: a “MAST”-er switch in COPD?	316
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	289
Missing airways, ventilation defects and conductive airway physiology in asthma	213
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	197
A breath of the future: a novel human model for COPD and beyond	184
The lung that rules the heart	177
Randomised controlled trials utilisingF_ENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	141
Gene–environment interaction at 17q12–q21 locus and its role in asthma pathogenesis	135
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	134
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	129
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	120
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	118
Soteria: deliverance from harm?	118
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	117
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	115
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	113
Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?	112
From spatial transcriptomics to mouse model: the (re-)emergence of ductal myofibroblasts as a new cellular target in idiopathic pulmonary fibrosis	109
Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges	103
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	101
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	101
Pulmonary hypertension associated with hereditary haemorrhagic telangiectasia: from genetics to clinical management	99
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	95

Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	94
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	90
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	89
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	89
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	89
Treatment algorithm for pulmonary arterial hypertension	88
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	85
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	84
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	83
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	83
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	79
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	78
Antiviral CD8⁺T-cell immune responses are impaired by cigarette smoke and in COPD	77
Associations between High-Density Lipoprotein Cholesterol and Interstitial Lung Abnormalities in the Korean National Lung Cancer Screening	74
sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension	73
A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease	71
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	71
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	65
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment	64
Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomised controlled trial	64
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study	64
No exposure left behind: time to pay attention to children's chemical environment in lung development	64
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	63
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis	62
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?	61
The limits of normal of pulmonary arterial wedge pressure	61
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	60
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough	59
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	58
Pleural mesothelioma: surgery questioned again?	58
FEV₁Q: what (even) is normal lung function?	57
List ofEuropean Respiratory Journalpeer reviewers 2023	57